Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias

International Journal of Hematology

Volumn 75, Issue 1, 2002, Pages 40-44

  Meletis, John ^a   Terpos, Evangelos ^a   Samarkos, Michalis ^a   Meletis, Christos ^b   Apostolidou, Effie ^a   Komninaka, Veroniki ^a   Korovesis, Konstantinos ^a   Anargyrou, Konstantinos ^a   Benopoulou, Olga ^a   Mavrogianni, Despina ^a   Variami, Eleni ^a   Viniou, Nora ^a   Konstantopoulos, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

CD55; CD59; Multiple myeloma; Paroxysmal nocturnal hemoglobinuria; Waldenstr m macroglobulinemia

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR;

ARTICLE; ERYTHROCYTE; HEAVY CHAIN DISEASE; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PLASMA CELL DYSCRASIA; WALDENSTROEM MACROGLOBULINEMIA; ADULT; AGED; BLOOD; CHEMISTRY; COMPARATIVE STUDY; ERYTHROCYTE MEMBRANE; FEMALE; HEMAGGLUTINATION TEST; HEMOLYSIS; IMMUNOPHENOTYPING; MALE; METHODOLOGY; MIDDLE AGED; PARAPROTEINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD55; ANTIGENS, CD59; ERYTHROCYTE MEMBRANE; FEMALE; HEAVY CHAIN DISEASE; HEMAGGLUTINATION TESTS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS; IMMUNOPHENOTYPING; MALE; MICROCHEMISTRY; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; WALDENSTROM MACROGLOBULINEMIA;

EID: 0036358249     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02981977     Document Type: Article

References (23)

1. Rotoli B, Luzzatlo L. Paroxysmal nocturnal hemoglobinuria. Semin Hematol. 1989;26:201-207.
2. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol. 1996;3:101-110.
3. Rosti V. The molecular basis of paroxysmal nocturnal hemoglobinuria. Haematologica. 2000;85:82-87.
4. Rosse WF, Ware R. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood. 1995;86:3277-3286.
5. Murakami Y, Kinoshita T, Maeda Y, Nakano T, Kosaka H, Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria. Blood. 1999;94:2963-2970.
6. Griscelli-Bennaceur A, Gluckman E, Scrobohaci ML, et al. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Blood. 1995;85:1354-1363.
7. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131:401-408.
8. Meletis J, Terpos E, Samarkos M, et al. Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders. Haematotogica (Budap). 2001;31:7-16.
9. Guc D, Canpinar H, Kucukaksu C, Kansu E. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies. Eur J Haematol. 2000;64:3-9.
10. Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995;86:1487-1492.
11. Meletis J, Terpos E, Samarkos M, et al. Detection of CD55 and/or CD59 deficient red cell populations in patients with lymphoproliferative syndromes. Hematol J. 2001;2:33-37.
12. Meletis J, Terpos E. Paroxysmal nocturnal haemoglobinuria: clinical presentation and association with other haematological disorders. Haema. 2001;4:79-88.
13. - erythrocytes in microtyping cards. Vox Sang. 1993;64:43-46.
14. Meletis J, Michali E, Samarkos M, et al. Detection of "PNH red cell" populations in hematological disorders using the Sephacryl Gel Test micro typing system. Leuk Lymphoma. 1997;28:177-182.
15. Fukuda H, Seya T, Hara T, Matsumoto M, Kinoshita T, Masaoka T. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin's lymphoma. Immunol Lett. 1991;29:205-209.
16. Seya T, Matsumoto M, Hara T, Hatanaka M, Masaoka T, Akedo H. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (CMP) and CD55 (DAF) in hematological malignancies. Leuk Lymphoma. 1994;12:395-400.
17. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci U S A. 1999;96:628-633.
18. Hillmen P, Richards SJ. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2000;108:470-479.
19. Taylor VC, Sims M, Brett S, Field MC. Antibody selection against CD52 produces a paroxysmal nocturnal hemoglobinuria phenotype in human lymphocytes by a novel mechanism. Biochem J. 1997;322:919-925.
20. Rawstron AC, Rollinson SJ, Richards S, et al. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol. 1999;107:148-153.
21. Araten D, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A. 1999;96:5209-5214.
22. Kwong YL, Lee CP, Chan TK, Chan TC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol. 1994;102:30-35.
23. Tremml G, Karadimitris A, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: learning about PNH cells from patients and mice. Haema. 1998;1:12-20.